Farah Abdulla
Farah Abdulla has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Helmstetter
Caris Life Sciences, Phoenix, USA
23 shared publications - Ari M. Vanderwalde
Caris Life Sciences, Phoenix, AZ 85040, USA
23 shared publications - Casey Bales
Caris Life Sciences (United States) 3 Phoenix, AZ
23 shared publications - David Bryant
Caris Life Sciences, Phoenix, AZ 85001, USA
23 shared publications - David Spetzler
Caris Life Sciences, Phoenix, USA
23 shared publications - Elena Florento
Caris Life Sciences, Irving, Texas
23 shared publications
Latest Publications
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Purpose:Radioactive iodine–refractory papillary thyroid cancers (PTC) containing BRAF V600E mutations can be treated with BRAF/MEK inhibitors (BRAF/MEKi), but their effectiveness compared with tyrosine kinase inhibitors (TKI) and immunotherapy (IO) remains unclear. Therefore, we compared real-world survival and molecular/transcriptional signatures in patients with BRAF V600E–mutated (BRAF-mut) and BRAF wild-type (WT) PTC.Experimental Design:Thyroid tumor samples underwent DNA/RNA next-generation sequencing and immunohistochemistry at Caris Life Sciences. Tumor microenvironment (TME) cell fractions were estimated by RNA deconvolution using quanTIseq. Insurance claims data were used to infer real-world overall survival (OS) and time on treatment.Results:A total of 1,348 patients with differentiated thyroid cancer were identified; 81.8% were classified as PTC, of which 68.4% harbored a BRAF V600E mutation. TERT promoter mutations were the most common mutation in PTC (72%) and were more prevalent in BRAF-mut versus BRAF-WT. Mutations in NRAS, HRAS, and KRAS, as well as RET, BRAF, and ETV6 gene fusions, were predominantly found in BRAF-WT PTC. BRAF-mut PTC were more often PD-L1+ (33% vs. 18%, P < 0.001) and had significantly higher IFNγ scores. OS was not significantly different between patients with BRAF-mut versus BRAF-WT PTC. Systemic treatment (BRAF/MEKi, TKI, or IO) was not associated with significant differences in OS in BRAF-mut PTC, although there was a trend for longer OS in those treated with TKI compared with BRAF/MEKi or IO.Conclusions:BRAF-mut PTC is associated with a proinflammatory TME milieu compared with BRAF-WT PTC. However, in this limited dataset, treatment choice was not associated with differences in OS in BRAF-mut PTC.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Purpose:Radioactive iodine–refractory papillary thyroid cancers (PTC) containing BRAF V600E mutations can be treated with BRAF/MEK inhibitors (BRAF/MEKi), but their effectiveness compared with tyrosine kinase inhibitors (TKI) and immunotherapy (IO) remains unclear. Therefore, we compared real-world survival and molecular/transcriptional signatures in patients with BRAF V600E–mutated (BRAF-mut) and BRAF wild-type (WT) PTC.Experimental Design:Thyroid tumor samples underwent DNA/RNA next-generation sequencing and immunohistochemistry at Caris Life Sciences. Tumor microenvironment (TME) cell fractions were estimated by RNA deconvolution using quanTIseq. Insurance claims data were used to infer real-world overall survival (OS) and time on treatment.Results:A total of 1,348 patients with differentiated thyroid cancer were identified; 81.8% were classified as PTC, of which 68.4% harbored a BRAF V600E mutation. TERT promoter mutations were the most common mutation in PTC (72%) and were more prevalent in BRAF-mut versus BRAF-WT. Mutations in NRAS, HRAS, and KRAS, as well as RET, BRAF, and ETV6 gene fusions, were predominantly found in BRAF-WT PTC. BRAF-mut PTC were more often PD-L1+ (33% vs. 18%, P < 0.001) and had significantly higher IFNγ scores. OS was not significantly different between patients with BRAF-mut versus BRAF-WT PTC. Systemic treatment (BRAF/MEKi, TKI, or IO) was not associated with significant differences in OS in BRAF-mut PTC, although there was a trend for longer OS in those treated with TKI compared with BRAF/MEKi or IO.Conclusions:BRAF-mut PTC is associated with a proinflammatory TME milieu compared with BRAF-WT PTC. However, in this limited dataset, treatment choice was not associated with differences in OS in BRAF-mut PTC.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Supplemental Table 2. GSEA gene sets with significant nominal p-values and associated ranks, metric, and enrichment score (ES).
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Supplemental Table 2. GSEA gene sets with significant nominal p-values and associated ranks, metric, and enrichment score (ES).
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Supplemental Table 1. Median gene expression by PTC BRAF-V600E vs BRAF-WT.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Supplemental Table 1. Median gene expression by PTC BRAF-V600E vs BRAF-WT.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Real-world overall survival (OS) in patients with BRAF-mut PTC treated with BRAF/MEKi, TKI or IO from Biopsy Date.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Real-world overall survival (OS) in patients with BRAF-mut PTC treated with BRAF/MEKi, TKI or IO from Biopsy Date.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Real-world survival (OS) associated with BRAF-V600E mutations in PTC by Biopsy Date.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Real-world survival (OS) associated with BRAF-V600E mutations in PTC by Biopsy Date.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Correlation of PD-L1 RNA expression and PD-L1 IHC.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Correlation of PD-L1 RNA expression and PD-L1 IHC.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Real-world survival (OS) associated with BRAF-V600E mutations in PTC.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Real-world survival (OS) associated with BRAF-V600E mutations in PTC.
- 16 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (6) , 1110-1119
Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Purpose: Radioactive iodine–refractory papillary thyroid cancers (PTC) containing BRAF V600E mutations can be treated with BRAF/MEK inhibitors (BRAF/MEKi), but their effectiveness compared with tyrosine kinase inhibitors (TKI) and immunotherapy (IO) remains unclear. Therefore, we compared real-world survival and molecular/transcriptional signatures in patients with BRAF V600E–mutated (BRAF-mut) and BRAF wild-type (WT) PTC. Experimental Design: Thyroid tumor samples underwent DNA/RNA next-generation sequencing and immunohistochemistry at Caris Life Sciences. Tumor microenvironment (TME) cell fractions were estimated by RNA deconvolution using quanTIseq. Insurance claims data were used to infer real-world overall survival (OS) and time on treatment. Results: A total of 1,348 patients with differentiated thyroid cancer were identified; 81.8% were classified as PTC, of which 68.4% harbored a BRAF V600E mutation. TERT promoter mutations were the most common mutation in PTC (72%) and were more prevalent in BRAF-mut versus BRAF-WT. Mutations in NRAS, HRAS, and KRAS, as well as RET, BRAF, and ETV6 gene fusions, were predominantly found in BRAF-WT PTC. BRAF-mut PTC were more often PD-L1+ (33% vs. 18%, P < 0.001) and had significantly higher IFNγ scores. OS was not significantly different between patients with BRAF-mut versus BRAF-WT PTC. Systemic treatment (BRAF/MEKi, TKI, or IO) was not associated with significant differences in OS in BRAF-mut PTC, although there was a trend for longer OS in those treated with TKI compared with BRAF/MEKi or IO. Conclusions: BRAF-mut PTC is associated with a proinflammatory TME milieu compared with BRAF-WT PTC. However, in this limited dataset, treatment choice was not associated with differences in OS in BRAF-mut PTC.
- 16 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (6) , 1110-1119
Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Purpose: Radioactive iodine–refractory papillary thyroid cancers (PTC) containing BRAF V600E mutations can be treated with BRAF/MEK inhibitors (BRAF/MEKi), but their effectiveness compared with tyrosine kinase inhibitors (TKI) and immunotherapy (IO) remains unclear. Therefore, we compared real-world survival and molecular/transcriptional signatures in patients with BRAF V600E–mutated (BRAF-mut) and BRAF wild-type (WT) PTC. Experimental Design: Thyroid tumor samples underwent DNA/RNA next-generation sequencing and immunohistochemistry at Caris Life Sciences. Tumor microenvironment (TME) cell fractions were estimated by RNA deconvolution using quanTIseq. Insurance claims data were used to infer real-world overall survival (OS) and time on treatment. Results: A total of 1,348 patients with differentiated thyroid cancer were identified; 81.8% were classified as PTC, of which 68.4% harbored a BRAF V600E mutation. TERT promoter mutations were the most common mutation in PTC (72%) and were more prevalent in BRAF-mut versus BRAF-WT. Mutations in NRAS, HRAS, and KRAS, as well as RET, BRAF, and ETV6 gene fusions, were predominantly found in BRAF-WT PTC. BRAF-mut PTC were more often PD-L1+ (33% vs. 18%, P < 0.001) and had significantly higher IFNγ scores. OS was not significantly different between patients with BRAF-mut versus BRAF-WT PTC. Systemic treatment (BRAF/MEKi, TKI, or IO) was not associated with significant differences in OS in BRAF-mut PTC, although there was a trend for longer OS in those treated with TKI compared with BRAF/MEKi or IO. Conclusions: BRAF-mut PTC is associated with a proinflammatory TME milieu compared with BRAF-WT PTC. However, in this limited dataset, treatment choice was not associated with differences in OS in BRAF-mut PTC.
- Open Access
- 1 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from GPSai: A Clinically Validated AI Tool for Tissue of Origin Prediction during Routine Tumor Profiling
Fusions as orthogonal evidence in cases with ‘Critical Value Discrepancies’.
- 1 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from GPSai: A Clinically Validated AI Tool for Tissue of Origin Prediction during Routine Tumor Profiling
Fusions as orthogonal evidence in cases with ‘Critical Value Discrepancies’.